Center For Asset Management LLC Purchases Shares of 3,430 Astrazeneca Plc $AZN

Center For Asset Management LLC purchased a new stake in shares of Astrazeneca Plc (NYSE:AZN) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 3,430 shares of the company’s stock, valued at approximately $315,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of AZN. Cibc World Market Inc. raised its position in shares of Astrazeneca by 21.5% in the 3rd quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock worth $4,942,000 after acquiring an additional 11,398 shares in the last quarter. TD Asset Management Inc raised its position in shares of Astrazeneca by 20.0% in the 3rd quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock worth $83,595,000 after acquiring an additional 181,273 shares in the last quarter. AMG National Trust Bank raised its position in shares of Astrazeneca by 20.4% in the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock worth $3,298,000 after acquiring an additional 7,289 shares in the last quarter. Y Intercept Hong Kong Ltd raised its position in shares of Astrazeneca by 111.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company’s stock worth $5,113,000 after acquiring an additional 35,148 shares in the last quarter. Finally, Oxbow Advisors LLC raised its position in shares of Astrazeneca by 96.2% in the 3rd quarter. Oxbow Advisors LLC now owns 77,594 shares of the company’s stock worth $5,953,000 after acquiring an additional 38,043 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Performance

Astrazeneca stock opened at $200.71 on Wednesday. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $311.28 billion, a P/E ratio of 30.64, a P/E/G ratio of 1.53 and a beta of 0.35. Astrazeneca Plc has a twelve month low of $122.48 and a twelve month high of $212.71.

Astrazeneca Announces Dividend

The business also recently declared a dividend, which was paid on Monday, March 23rd. Investors of record on Friday, February 20th were paid a $1.595 dividend. The ex-dividend date was Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca’s dividend payout ratio is presently 66.26%.

Wall Street Analysts Forecast Growth

AZN has been the subject of several research reports. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. HSBC reissued a “buy” rating and issued a $108.00 target price on shares of Astrazeneca in a research report on Wednesday, December 10th. Weiss Ratings initiated coverage on Astrazeneca in a research report on Wednesday, March 11th. They issued a “buy (b)” rating for the company. Barclays reissued an “overweight” rating on shares of Astrazeneca in a research report on Tuesday, January 6th. Finally, Wall Street Zen lowered Astrazeneca from a “buy” rating to a “hold” rating in a research report on Saturday. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Astrazeneca has an average rating of “Moderate Buy” and a consensus price target of $95.75.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.